RT Journal Article
SR Electronic
T1 Long-term course of humoral and cellular immune responses in outpatients after SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.24.21259218
DO 10.1101/2021.06.24.21259218
A1 Schiffner, Julia
A1 Backhaus, Insa
A1 Rimmele, Jens
A1 Schulz, Sören
A1 Möhlenkamp, Till
A1 Klemens, Julia Maria
A1 Zapf, Dorinja
A1 Solbach, Werner
A1 Mischnik, Alexander
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2021.06.24.21259218.abstract
AB Characterisation of the naturally acquired B and T cell immune responses to SARS-CoV-2 is important for the development of public health and vaccination strategies to manage the burden of COVID-19 disease. We conducted a prospective, longitudinal analysis in COVID-19 recovered patients at various time points over a 10-month period in order to determine how circulating antibody levels and interferon-gamma (IFN-γ) release by peripheral blood cells change over time following natural infection.From March 2020 till January 2021, we enrolled 412 adults mostly with mild or moderate disease course. At each study visit, subjects donated peripheral blood for testing of anti-SARS-CoV-2 IgG antibodies and IFN-γ release after SARS-CoV-2 S-protein stimulation. Anti-SARS-CoV-2 IgG antibodies were identified in 316/412 (76.7%) of the patients and 215/412 (52.2%) had positive neutralizing antibody levels. Likewise, in 274/412 (66.5 %) positive IFN-γ release and IgG antibodies were detected. With respect to time after infection, both IgG antibody levels and IFN-γ concentrations decreased by about half within three hundred days. Statistically, IgG and IFN-γ production were closely associated, but on an individual basis we observed patients with high antibody titres but low IFN-γ levels and vice versa.Our data suggest that immunological reaction is acquired in most individuals after infection with SARS-CoV-2 and is sustained in the majority of patients for at least 10 months after infection. Since no robust marker for protection against COVID-19 exists so far, we recommend utilizing both, IgG and IFN-γ release for an individual assessment of immunity status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the City of Luebeck and EUROIMMUN AGAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical committee of the University of Luebeck approved the study (ref. 20-339).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available if you contact the authors.COVID-19coronavirus disease 19Iconfidence intervalELISAEnzyme-linked Immunosorbent AssayIgGimmunoglobulin GIGRAInterferon-Gamma-Release Assayrt-PCRreal-time polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2